• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ClearPoint Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    6/17/25 4:15:28 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care
    Get the next $CLPT alert in real time by email
    8-K
    false 0001285550 0001285550 2025-06-16 2025-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 16, 2025

     

     

     

    CLEARPOINT NEURO, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware 001-34822 58-2394628
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number) (IRS Employer
    Identification No.)
         
    120 S. Sierra Ave., Suite 100    
    Solana Beach, California   92075
    (Address of Principal Executive Offices)   (Zip Code)
         

     

    Registrant’s Telephone Number, Including Area Code: 888 287-9109

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.01 par value per share   CLPT   The Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

       

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On June 16, 2025, ClearPoint Neuro, Inc. (“Company”), entered into a lease agreement (the “Lease Agreement”) with BRE-BMR SCD LLC (the “Lessor”), to expand into approximately 30,171 square feet within a life science building located in San Diego, California (the “Leased Premises”). The Company will use the Leased Premises for office, research and development, and laboratory purposes.

     

    The Leased Premises will be occupied in three phases, the first of which is expected to be occupied by June 13, 2025. The second and third phases are expected to be occupied by December 19, 2025 and July 1, 2026, respectively. The Lease Agreement expires 132 months from the date on which the last phase is occupied, subject to the Company’s right to extend the lease term for one additional five-year period. The Lessor will perform certain improvements to the Leased Premises on a turn-key basis pursuant to plans agreed upon by the Company and the Lessor. The initial monthly base rent payable under the Lease Agreement is $5.95 per square foot, with payment of base rent for the first and second phases to commence after occupation of the second phase and with payment of base rent for the third phase to commence after occupation of the third phase of the Leased Premises. The monthly base rent will be abated (i) for the 2nd through 13th months after the second phase occupation solely as to the first and second phase of the Leased Premises, and (ii) for the 1st through 12th months after the third phase occupation solely as to the third phase of the Leased Premises. The base rent is subject to annual increases of 3% during the lease term, with the increases to commence upon the first anniversary date of the later to occur of the occupation of the second or third phase of the Leased Premises. In addition to the base rent, the Company is responsible for its pro rata share of operating expenses, including insurance and taxes, with such charges to commence upon the Company’s occupation of the first phase premises.

     

    In addition, the Company is required to provide the Lessor with a letter of credit in the amount of $179,517.45 as security for performance of the Company’s obligations under the Lease Agreement.

     

    The foregoing summary of the material terms of the Lease Agreement does not purport to be a complete description of the Lease Agreement and is qualified in its entirety by reference to the full text of the Lease Agreement (with certain confidential terms redacted, as indicated thereon), which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No. Description
       
    10.1* Lease dated as of June 16, 2025, by and between BRE-BMR SCD LLC, a Delaware limited liability company, and ClearPoint Neuro, Inc.
       
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
       

     *Confidential portions of this exhibit have been redacted.

     

     

     

     

     

     2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CLEARPOINT NEURO, INC.
         
    Date: June 17, 2025 By: /s/ Danilo D'Alessandro
        Danilo D'Alessandro
    Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     3 

     

    Get the next $CLPT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLPT

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    More analyst ratings

    $CLPT
    SEC Filings

    See more
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      6/17/25 4:15:28 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by ClearPoint Neuro Inc.

      144 - ClearPoint Neuro, Inc. (0001285550) (Subject)

      6/3/25 4:13:31 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      5/23/25 4:30:10 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

      7/25/24 8:27:37 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on ClearPoint Neuro with a new price target

      Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

      10/24/23 6:18:03 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

      2/16/23 7:44:43 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/12/24 2:35:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/8/24 4:33:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/4/24 11:28:38 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer D'Alessandro Danilo was granted 376 shares, increasing direct ownership by 0.57% to 66,368 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:13:49 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Business Officer Stigall L. Jeremy was granted 1,608 shares, increasing direct ownership by 2% to 72,355 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:11:30 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Chief Operating Officer Sabra Mazin was granted 361 shares, increasing direct ownership by 0.71% to 51,564 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      7/2/25 5:08:46 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

      Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

      11/13/24 1:20:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports Third Quarter 2024 Results

      Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

      11/7/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

      President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

      10/31/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLPT
    Leadership Updates

    Live Leadership Updates

    See more
    • ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

      SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

      9/20/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

      SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

      8/8/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

      SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

      7/15/21 4:30:00 PM ET
      $CLPT
      $ACLS
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Technology

    $CLPT
    Financials

    Live finance-specific insights

    See more
    • ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

      SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

      10/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

      SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

      7/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

      SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

      4/23/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care